BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35668443)

  • 21. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
    Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
    Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.
    Farrand L; Kim JY; Byun S; Im-aram A; Lee J; Suh JY; Lee KW; Lee HJ; Tsang BK
    J Biol Chem; 2014 Jan; 289(3):1723-31. PubMed ID: 24247248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p62 Promotes the Mitochondrial Localization of p53 through Its UBA Domain and Participates in Regulating the Sensitivity of Ovarian Cancer Cells to Cisplatin.
    Kong Q; Yan X; Cheng M; Jiang X; Xu L; Shen L; Yu H; Sun L
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
    Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
    Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
    Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
    Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death.
    Wang J; Guo W; Zhou H; Luo N; Nie C; Zhao X; Yuan Z; Liu X; Wei Y
    Oncotarget; 2015 Jul; 6(19):17192-205. PubMed ID: 25980443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
    Gagliardi S; Mitruccio M; Di Corato R; Romano R; Aloisi A; Rinaldi R; Alifano P; Guerra F; Bucci C
    Cell Commun Signal; 2024 Mar; 22(1):165. PubMed ID: 38448982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
    Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
    Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53.
    Lu P; Vander Mause ER; Redd Bowman KE; Brown SM; Ahne L; Lim CS
    J Ovarian Res; 2019 May; 12(1):45. PubMed ID: 31092272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An improved quantitative approach for the assessment of mitochondrial fragmentation in chemoresistant ovarian cancer cells.
    Farrand L; Kim JY; Im-Aram A; Suh JY; Lee HJ; Tsang BK
    PLoS One; 2013; 8(9):e74008. PubMed ID: 24040144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study.
    Kamińska I; Bar JK
    Pharmacol Rep; 2018 Jun; 70(3):570-576. PubMed ID: 29684847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
    Im-aram A; Farrand L; Bae SM; Song G; Song YS; Han JY; Tsang BK
    PLoS One; 2013; 8(9):e75455. PubMed ID: 24086535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer.
    Han CY; Patten DA; Lee SG; Parks RJ; Chan DW; Harper ME; Tsang BK
    Mol Carcinog; 2019 Nov; 58(11):2161-2174. PubMed ID: 31486135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
    Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
    J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.
    Hu W; Wang F; Tang J; Liu X; Yuan Z; Nie C; Wei Y
    J Biol Chem; 2012 Jan; 287(1):68-80. PubMed ID: 22052903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.